The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy
Authors:
- 1 April 2016
- journal article
- review article
- Published by Elsevier in Journal of the American Society of Hypertension
- Vol. 10 (4) , 352-359
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Thrombotic microangiopathy and associated renal disordersNephrology Dialysis Transplantation, 2012
- Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenibClinical and Experimental Pharmacology and Physiology, 2012
- Contribution of oxidative stress to endothelial dysfunction in hypertensionFrontiers in Physiology, 2012
- Xanthine Oxidase Inhibition For The Treatment Of Cardiovascular Disease: A Systematic Review and Meta‐AnalysisCardiovascular Therapeutics, 2011
- Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 2010
- The Renin Angiotensin Aldosterone System in Hypertension: Roles of Insulin Resistance and Oxidative StressMedical Clinics of North America, 2009
- Association Between Thrombotic Microangiopathy and Reduced ADAMTS13 Activity in Malignant HypertensionHypertension, 2008
- Thrombotic Microangiopathy in Malignant Hypertension and Hemolytic Uremic Syndrome (HUS)/Thrombotic Thrombocytopenic Purpura (TTP): Can We Differentiate One from the Other?Hypertension Research, 2005
- Hemolytic-Uremic Syndrome and Complement Factor H Deficiency: Clinical AspectsSeminars in Thrombosis and Hemostasis, 2001
- The endothelium. Target and promoter of hypertension?Hypertension, 1990